Search Medical Condition
Please enter condition
Please choose location from dropdown

Berea, South Africa Clinical Trials

A listing of Berea, South Africa clinical trials actively recruiting patients volunteers.

RESULTS

Found (71) clinical trials

A Study of Atezolizumab (Anti Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

This study will evaluate the efficacy and safety of atezolizumab compared with placebo as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck (SCCHN)

Phase

1.08 miles

Learn More »

Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa

This study will evaluate the preventive vaccine efficacy, safety, and tolerability of the ALVAC-HIV vaccine + Bivalent Subtype C gp120 protein adjuvanted with MF59 in HIV-seronegative South African adults over 24 months from enrollment. Participants will be randomized to receive ALVAC-HIV (vCP2438), or placebo, by intramuscular injection at weeks 0 ...

Phase

1.3 miles

Learn More »

Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine

This study will evaluate the safety, tolerability, and immunogenicity to vCP2438 (an HIV clade C vaccine) and to an unadjuvanted or MF59- or alum-adjuvanted bivalent clade C gp120 in healthy, HIV-uninfected adults. The study will enroll healthy, HIV-uninfected participants aged 18 to 40 years. Participants will be randomly assigned to ...

Phase

1.3 miles

Learn More »

Paediatric and Adult African Spirometry II

Pulmonary function testing is the most widely used tool for the diagnosis, severity assessment, management, risk factor categorization and follow-up of individuals with chronic lung disease. Africa has a high burden of infectious respiratory diseases which include tuberculosis and human immunodeficiency virus-related lung disease.Coupled with this is an increasing burden ...

Phase N/A

1.3 miles

Learn More »

Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women

This study will evaluate the safety, tolerability, and efficacy of the VRC01 antibody in preventing HIV-1 infection in healthy women at high risk of HIV infection. Participants will be enrolled from a cohort of heterosexual women in sub-Saharan Africa. An equal number of study participants will be randomized to receive ...

Phase

1.3 miles

Learn More »

Prevention of Female Genital Schistosomiasis (FGS) in Rural High-endemic South Africa

Provide a more extensive description, if desired. Avoid duplication of information to be recorded elsewhere, such as eligibility criteria or outcome measures

Phase N/A

1.61 miles

Learn More »

Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women

Background It is becoming increasingly evident that women remain vulnerable to HIV infection during pregnancy and even more so postdelivery. In a meta-analysis, using data from 19 international cohorts, Drake et al concluded that the pooled HIV incidence rate during pregnancy/postpartum was 3.8/100 PWY (95% CI 3.0-4.6): 4.7/100 PWY during ...

Phase

1.73 miles

Learn More »

Observational Study of HIV Infected Women Previously Enrolled in Other Microbicide Trials

It is necessary to monitor HIV over long periods of time in order to better understand the impact of microbicides and anti-HIV drugs on the progression of HIV infection in those who become infected or are unknowingly already infected while receiving these drugs. The purpose of this study is to ...

Phase N/A

1.73 miles

Learn More »

A Study to Evaluate the Pharmacokinetics Safety Tolerability and Antiviral Efficacy of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

This is a Phase II, open-label (all people involved know the identity of the assigned drug) and single arm study. The study will consist of a screening period of maximum 8 weeks, an initial treatment period of 48 weeks, a post week 48 treatment extension period of 4 years, and ...

Phase

1.73 miles

Learn More »

A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis

The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive.

Phase

1.73 miles

Learn More »